|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.52 USD | -2.43% |
|
-1.96% | +78.09% |
| 05/03 | Berenberg Raises Price Target on Moderna to $45 From $32, Keeps Hold Rating | MT |
| 05/03 | US stocks close up on Iran diplomacy hopes; tech leads rebound | RE |
| Capitalization | 2.07TCr 1.79TCr 1.61TCr 1.55TCr 2.82TCr 1,90600Cr 2.96TCr 19TCr 7.65TCr 91TCr 7.78TCr 7.62TCr 3,26900Cr | P/E ratio 2026 * |
-7.57x | P/E ratio 2027 * | -11.5x |
|---|---|---|---|---|---|
| Enterprise value | 1.69TCr 1.46TCr 1.31TCr 1.26TCr 2.3TCr 1,55100Cr 2.41TCr 16TCr 6.22TCr 74TCr 6.33TCr 6.2TCr 2,66000Cr | EV / Sales 2026 * |
8.17x | EV / Sales 2027 * | 7.23x |
| Free-Float |
90.48% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Moderna, Inc.
| 1 day | -2.43% | ||
| 1 week | -1.96% | ||
| Current month | -1.96% | ||
| 1 month | +28.07% | ||
| 3 months | +89.60% | ||
| 6 months | +108.91% | ||
| Current year | +78.09% |
| 1 week | 48.09 |  | 59.55 |
| 1 month | 36.66 | | 59.55 |
| Current year | 29.81 | | 59.55 |
| 1 year | 22.28 | | 59.55 |
| 3 years | 22.28 | | 170.47 |
| 5 years | 22.28 | | 497.49 |
| 10 years | 11.54 | | 497.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 54 | 01/03/2011 |
James Mock
DFI | Director of Finance/CFO | 49 | 06/09/2022 |
Stephen Hoge
PSD | President | 50 | 01/11/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Paul Sagan
BRD | Director/Board Member | 66 | 01/06/2018 |
Noubar Afeyan
CHM | Chairman | 62 | 01/02/2012 |
Stéphane Bancel
BRD | Director/Board Member | 54 | 01/03/2011 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.43% | -1.96% | +53.12% | -63.54% | 2.13TCr | |
| -0.66% | -2.79% | +8.79% | -2.63% | 7.85TCr | |
| -2.68% | -0.52% | +30.70% | +212.11% | 5.68TCr | |
| -0.18% | +64.40% | +64.40% | +64.40% | 5.13TCr | |
| -0.15% | -0.33% | -44.17% | -50.33% | 4.92TCr | |
| -1.71% | -3.62% | +25.45% | -31.59% | 2.76TCr | |
| -1.43% | -5.26% | +36.88% | +26.49% | 1.94TCr | |
| +6.18% | -2.12% | +106.44% | +96.23% | 1.74TCr | |
| -1.21% | -4.75% | +24.78% | +56.33% | 1.42TCr | |
| +0.27% | -8.47% | -4.48% | +912.21% | 1.34TCr | |
| Average | -0.40% | -3.74% | +30.19% | +121.97% | 3.49TCr | |
| Weighted average by Cap. | -0.73% | -3.19% | +23.65% | +73.46% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 206.69Cr 178.21Cr 160.87Cr 154.36Cr 281.47Cr 19TCr 294.57Cr 1.9TCr 761.88Cr 9.11TCr 775.73Cr 759.19Cr 33TCr | 253.17Cr 218.28Cr 197.05Cr 189.07Cr 344.77Cr 23TCr 360.82Cr 2.33TCr 933.2Cr 11TCr 950.16Cr 929.91Cr 40TCr |
| Net income | -273.83Cr -236.1Cr -213.13Cr -204.5Cr -372.91Cr -25TCr -390.26Cr -2.52TCr -1.01TCr -12TCr -1.03TCr -1.01TCr -43TCr | -181.72Cr -156.68Cr -141.44Cr -135.71Cr -247.47Cr -17TCr -258.99Cr -1.67TCr -669.84Cr -8.01TCr -682.02Cr -667.48Cr -29TCr |
| Net Debt | -386.48Cr -333.22Cr -300.81Cr -288.63Cr -526.31Cr -36TCr -550.81Cr -3.56TCr -1.42TCr -17TCr -1.45TCr -1.42TCr -61TCr | -244.42Cr -210.74Cr -190.24Cr -182.54Cr -332.86Cr -22TCr -348.35Cr -2.25TCr -900.96Cr -11TCr -917.34Cr -897.78Cr -39TCr |
Employees
4,700
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/26/06 | 52.52 $ | -2.43% | 1,24,10,103 |
| 05/26/05 | 53.83 $ | -6.87% | 1,39,53,534 |
| 04/26/04 | 57.80 $ | +15.99% | 2,31,03,642 |
| 03/26/03 | 49.83 $ | -5.71% | 92,58,801 |
| 02/26/02 | 52.84 $ | -1.35% | 94,24,727 |
Sell
Buy
Mean consensus
HOLD
Number of Analysts
24
Last Close Price
52.52USD
Average target price
42.90USD
Spread / Average Target
-18.32%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRNA Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition